5th Biennial Biosimilars & Biobetters Congress

November 22, 2017

Over the past editions our 5th Biennial Biosimilars & Biobetters Congress has built up a reputation for delivering high-level content and bringing together the top senior executives and leaders within the Biosimilar industry. We would like to share with you some of the many highlights you should not miss from our 2018 conference programme: Day […]

DSM Expands Strategic Alliance with Amyris and Acquires Brazilian Production Facility from Amyris

November 20, 2017

MILAN, November 17, 2017 /PRNewswire/ —   Royal DSM (AEX: DSM.AS), a global science-based company active in health, nutrition and materials and Amyris, Inc. (Nasdaq: AMRS), the industrial bioscience company, today announced that they have enhanced their strategic alliance through the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing […]

BioQ Pharma and Sophos Biotech Enter into Strategic Partnership for Post-Operative Analgesia Therapy in Italy

November 20, 2017

ROME and SAN FRANCISCO, Nov. 20, 2017 (GLOBE NEWSWIRE) — BioQ Pharma Incorporated (“BioQ”) and Sophos Biotech S.r.l. (“Sophos”), both specialty pharmaceutical companies, today announced a strategic partnership agreement under which BioQ will supply and Sophos will commercialize a proprietary treatment for post-operative pain management in Italy. The product is a 48-hour opioid sparing post-surgical […]

WIRB-Copernicus Group Partners with Veeva Systems Inc.

November 20, 2017

WCG will create a seamless connection between WCG’s MyConnexus™ IRB document management web portal and Veeva Vault eTMF WIRB-Copernicus Group® (WCG™), the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced that it is partnering with Veeva Systems Inc. to improve the speed and accuracy of institutional review […]

Comprehend Systems Appoints New CEO in Response to Surging Demand for Clinical Intelligence Solutions; Enterprise Growth Expert to Scale Company and Expand Partner Ecosystem

November 20, 2017

Redwood City, Calif., November 13, 2017—Comprehend Systems, Inc., the leader in Clinical Intelligence solutions, has named Terry Cunningham CEO.  Cunningham will focus on scaling Comprehend in response to explosive customer demand for solutions that reduce time and risk in clinical trials. Cunningham will also drive expanded partner programs to help sponsors achieve faster, better clinical […]

Elizabeth Iorns, Ph.D., CEO of Science Exchange Elected to the Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT)

November 15, 2017

Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced today that Elizabeth Iorns, Ph.D., CEO of Science Exchange, has been elected to serve her first term on the Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT) beginning November 1, 2017. Members of […]

Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195

November 14, 2017

STAMFORD, Conn., Nov. 14, 2017 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that it has entered into a global collaboration with Bayer to develop and commercialize larotrectinib and LOXO-195, Loxo Oncology’s franchise of highly selective TRK inhibitors […]

Science Exchange Scientific Provider Elion Labs presenting New Research at the AAPS Annual Meeting: Breakthrough in Drug Product Particle Analysis Using Machine Learning

November 13, 2017

Biopharma researchers can access Elion’s new services from PALO ALTO, CA, and LOUISVILLE, CO – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development, is proud to announce that Elion Labs, provider of analytical development and drug product characterization services, will present exciting new research at the 2017 AAPS […]

Sosei to Advance Clinical Development in Japan of HTL0018318 in Patients with Dementia with Lewy Bodies (DLB)

November 9, 2017

TOKYO & LONDON–(BUSINESS WIRE)–Sosei Group Corporation (“Sosei”); TSE Mothers Index:4565) announces that it has agreed with Allergan to an amendment to the 2016 global R&D and commercialisation partnership between Allergan and Sosei’s subsidiary Heptares Therapeutics, in which Allergan gained exclusive rights to Heptares’ broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the […]

Sanofi, Principia agree to develop multiple sclerosis drug candidate

November 9, 2017

Paris, France and South San Francisco, Calif – November 9, 2017 – Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases.   Under the license agreement signed this week, Sanofi will develop Principia’s Bruton’s tyrosine kinase (BTK) inhibitor (PRN2246), which […]

REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

November 8, 2017

PALO ALTO, Calif.– Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exchange platform as the primary marketplace to offer access to its predictive drug discovery assays for the biopharma research community. With REPROCELL as one of […]

The Pistoia Alliance AbVance Project Reaches a Key Milestone with First Release of Antibody Structures into the Protein Data Bank

November 8, 2017

The AbVance project aims to accelerate biologics drug discovery by increasing knowledge of antibody structures in the public domain  The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D has announced today that its project to increase  knowledge of antibody (Ab) structures has reached its […]

Growing Biomedical Research Organization AMPEL BioSolutions Selects Montrium as eTMF Partner

November 7, 2017

Charlottesville, Virginia (November 7, 2017) — Today, Montrium announced that AMPEL BioSolutions has chosen Montrium’s eTMF Connect platform as their eTMF management solution. Finding an experienced technology partner was key for AMPEL BioSolutions as they are looking to scale research efforts and continue growth. With over a decade of providing best-in-class technology products & professional […]

Amgen And Novartis Announce Expanded Collaboration With Banner Alzheimer’s Institute In Pioneering Prevention Program

November 3, 2017

THOUSAND OAKS, Calif., Nov. 2, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Novartis today announced an expanded collaboration with the Banner Alzheimer’s Institute (BAI) to initiate a new trial – the Alzheimer’s Prevention Initiative (API) Generation Study 2. This trial follows the launch of the Generation Study 1, and will determine whether the BACE1 inhibitor CNP520 […]

Sarepta Therapeutics Signs Exclusive Global Collaboration with Duke University for Gene Editing CRISPR/Cas9 Technology to Develop New Treatments for Duchenne Muscular Dystrophy (DMD)

October 31, 2017

CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that it has signed a research collaboration agreement with Duke University, granting the Company an option to an exclusive license to intellectual […]

Sumitomo Dainippon Pharma and Poxel Announce Strategic Partnership for Development and Commercialization of Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan, China and Eleven Other Asian Countries

October 30, 2017

Osaka, Japan and Lyon, France, October 30, 2017 – Sumitomo Dainippon Pharma Co., Ltd (Head Office: Osaka, Japan; President: Masayo Tada; Securities Code: 4506, First Section of TSE, hereinafter called “Sumitomo Dainippon Pharma”) and POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including […]

Certara-Monash University Industry Fellowship Program Receives Funding from MTPConnect’s Project Fund Program

October 26, 2017

Fellowship program recognised as a big, bold idea to improve the productivity, competitiveness and innovative capacity of Australia’s medtech, biotech and pharmaceutical sector MTPConnect – the Medical Technologies and Pharmaceuticals Industry Growth Centre – today announced it will provide a proposed AUD750,000 provisional funding to the Certara-Monash University Industry Fellowship Program over two years, with […]

ERT Support for New Drug Development Exceeds 10,000 Studies

October 26, 2017

ERT Support for New Drug Development Exceeds 10,000 Studies Extensive experience enables biopharmaceutical researchers to better navigate clinical trial complexities and minimize risks PHILADELPHIA – October 25, 2017 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced it has reached a significant milestone in its nearly […]

Elsevier announces winners of the 2017 Reaxys PhD Prize

October 25, 2017

Three young chemistry researchers recognized for their innovative and original research Elsevier, the information analytics business specializing in science and health, announced the three winners of the 2017 Reaxys PhD Prize at its annual Symposium held in Shanghai, China. Celebrating top research by leading young chemists across the globe, the Reaxys PhD Prize recognizes innovative […]

Vical Announces Joint Development Program With AnGes on a Treatment for Chronic Hepatitis B Infection

October 24, 2017

SAN DIEGO, Oct. 24, 2017 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) announced today that it is pursuing early stage development of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. This development effort is being conducted in collaboration with Vical’s strategic partner, AnGes, Inc of Osaka, Japan. […]

Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG

October 24, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) announced today that it has increased the profit potential on aducanumab, its Phase 3 investigational treatment for early Alzheimer’s disease, by reducing the potential royalty payment on potential commercial sales of aducanumab to Neurimmune Holding AG. In exchange for a 15 percent reduction in the previously negotiated royalty rates, Biogen […]

Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab

October 23, 2017

CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments.   Under the terms of the agreement Eisai has […]

Inspyr Therapeutics Announces Research Collaboration with the National Institutes of Health

October 23, 2017

WESTLAKE VILLAGE, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) — Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company, announced the initiation of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. This preclinical study, led by Elizabeth Kang, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the […]

Roivant Sciences Enters into Development Partnership with AstraZeneca

October 20, 2017

BASEL, Switzerland, Oct. 19, 2017 /PRNewswire/ — Roivant Sciences today announced that it has entered into a development partnership with AstraZeneca for a deprioritized investigational drug in an undisclosed indication. The drug will be developed by Roivant in a new therapeutic area that is outside of AstraZeneca’s main therapy areas. Roivant has licensed global rights […]

Boehringer Ingelheim partners with TARGET PharmaSolutions to Progress NASH Research

October 20, 2017

CHAPEL HILL, N.C., Oct. 19, 2017 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Boehringer Ingelheim International GmbH has entered into a multi-year strategic partnership for TARGET-NASH.   TARGET-NASH is a longitudinal observational study that evaluates patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). To […]

Corrona and the National Multiple Sclerosis Society announce intent to collaborate on a multiple sclerosis registry to study the comparative effectiveness and safety of approved therapies

October 20, 2017

WALTHAM, Mass., Oct. 20, 2017 /PRNewswire/ — Corrona, LLC and the National Multiple Sclerosis Society have announced their intent to collaborate on the launch of the Corrona Multiple Sclerosis (MS) Registry to study the comparative safety and effectiveness of approved MS therapies. The first patient has been enrolled, with initial recruitment goals to register approximately […]

Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines

October 19, 2017

SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) — Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The two companies will work together to develop and commercialize […]

Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases

October 18, 2017

Osaka, Japan and Charlottesville, Va. – Oct. 17, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH). “The ability to study pathophysiology in a human multi-cell system is crucial for […]

NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research

October 18, 2017

LUND, Sweden, Oct. 18, 2017 /PRNewswire/ — NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that NeuroVive and Ramin Massoumi at Lund University have been granted 2.5 MSEK from the Swedish Foundation for Strategic Research (SFF) for an Industrial PhD to study the role of cyclophilins in liver cancer. […]

SCORR Marketing and Applied Clinical Trials Release Report on Collaborative R&D in the Drug Development Industry

October 18, 2017

Kearney, Neb., Oct. 18, 2017 (Business Wire) — SCORR Marketing, a global health science marketing and communications firm, and Applied Clinical Trials have released a new study, Collaborative R&D Survey Report. The report details the extent to which collaboration in the life sciences industry occurs and provides insight into the factors that influence this collaboration. […]